Intestinal Barrier

Summary

Intestinal Barrier at its maximum: repairs, reduces inflammation, seals, and strengthens gut immunity with BPC-157 (mucosa), KPV (anti-inflammatory), Larazotide (tight junctions), and Thymosin Alpha-1 (immune modulation of the gut-immunity axis).

Why is it being researched?

• •  Intestinal mucosa repair
• •  Reduction of digestive inflammation
• •  Barrier integrity (tight junctions)
• •  Strengthening of the gut-immunity axis

Formula Composition

Cycle and Rest

Administration

A single application, no multiple injections. Designed for simple administration.

Mechanism of action

BPC-157 — mucosal repair

Protects and regenerates the gastrointestinal lining and stabilizes the endothelium.

KPV — anti-inflammatory

C-terminal tripeptide of α-MSH with potent local anti-inflammatory action.

Larazotide — tight junctions

Regulates tight junctions, reducing permeability and "sealing" the barrier.

Thymosin Alpha-1 — gut-immunity axis

Modulates the immune system (a large part of which resides in the gut), strengthening the barrier's defense.

Synergy

Repair (BPC-157) + reduce inflammation (KPV) + seal (Larazotide) + strengthen immunity (Thymosin Alpha-1).

Scientific Evidence

Larazotide: AT-1001, evaluated in clinical trials on intestinal permeability and celiac disease.

BPC-157: Mucosal repair in models of gastrointestinal damage.

Thymosin Alpha-1: Reference immunomodulator in research.

Product Use

Intestinal Barrier is an exclusive formula, available only at Peptido BioGenetic. High-purity research material, with Certificate of Analysis (COA) available upon request.

⚠️ Product intended exclusively for research and laboratory use. Not suitable for human or veterinary consumption.